The IACT project (FP7) website is up and running


LeadArtis is a partner of the IACT (Immunostimulatory Agonist Antibodies for Cancer Therapy) 6.9M€ funding consortium (Project Number: 602262). The IACT is an interdisciplinary platform that involves a total of 10 partners with long-standing expertise in agonist immunostimulatory antibodies (IS-Abs), from research institutions and small-medium enterprises (SEM) located in five European countries (Germany, Italy, Spain, Sweden and United Kingdom).

Escherichia coli offers short-cut to large-scale Trimerbody® manufacturing


Trimerbody® is a unique mono/multispecific antibody format based on the use of specific collagen trimerization domains and optimized peptide linkers. Trimerbodies are trimeric in solution and exhibit excellent antigen binding capacity and stability in vitro and in vivo.

LeadArtis participates in the first IACT scientific update meeting


The first IACT review meeting took place on November 17-18, 2014 in Frankfurt, Germany. Representatives of all partners, including management and scientific teams participated in the assembly.

Leadartis announces its partnership in the TERET project.


Leadartis is proud to announce its participation as a partner in the TERET project (New Treatments for Degenerative Retina Diseases) funded by the Spanish Ministry of Economy and Competitiveness (MINECO) under the RETOS of the society program. The MINECO’s participation demonstrates its support of Leadartis technology research and main objectives.

Leadartis reports its business strategy at BioSpain 2014


Leadartis has participated in BioSpain 2014 recently held in Santiago de Compostela (November 24-26th). BioSpain was chosen to present our business to the sector since is the most important biotechnology event in Spain and one of the most important internationally.

Leadartis announces the appointment of Dr. Francisco Sanchez-Madrid as a member of its Scientific Advisory Board


Madrid (September 4th, 2014). Leadartis, a privately held biotechnology company, is pleased to announce the appointment of Dr. Francisco Sanchez-Madrid as a member of its Scientific Advisory Board (SAB). Dr. Sanchez-Madrid together with the outstanding scientists and drug development professionals: Dr. L. Alvarez-Vallina, Dr. P. Kristensen, Dr. I. Melero and Dr. L.

Leadartis to present its business at BioSpain 2014 on September 24th, 2014


Madrid (September 3rd). Leadartis, a privately held biotechnology company, is pleased to announce is participation at the BioSpain 2014 international biotechnology conference to be held in Santiago de Compostela (Spain) in September, 24th-26th, 2014

Leadartis reports an efficient method for production of Trimerbody® molecules in Pichia Pastoris


In collaboration with prestigious academic institutions, LeadArtis´scientists demonstrated that single-chain fragment variable (scFv)-based N-terminal Trimerbody® molecules can be efficiently produced in the methylotrophic yeast Pichia pastoris (P. pastoris) in a trimeric fully functional active form. The yield of scFv-based N-terminal Trimerbody® molecules expressed in P. pastoris was about 20-fold higher than in mammalian cells. New marketed therapeutic proteins produced in Pichia evidence the rising interest of P.

LeadArtis announces the appointment of Dr. Juan J. Perez Villar as CEO.


In his new position, Juan will be responsible for raising investment capital, providing strategic leadership and overseeing operations for the Company. Juan brings more than 18 years of experience in the sector having previously served as Business Development Partner at Biolty (Madrid, Spain), prior to that Juan was Director of the industrial affairs department at the CEU University (Valencia, Spain) and head of oncology group at Astellas/Agensys (Santa Monica, CA, USA) and Bristol Myers Squibb (Princeton, NJ, USA). Juan earned a M.S. in biochemistry and a Ph.D.

Syndicate content

Latest News

LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....

LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy

LeadArtis´scientists, in collaboration with other prime...

Leadartis successfully accomplishes the TERET project

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...